Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and manufacturing of next-generation protein therapeutics for oncology and immune-related diseases. Its proprietary cell-free protein synthesis platform, XpressCF, enables precise engineering of complex biologic drugs, including antibody-drug conjugates and targeted protein therapies. Key pipeline candidates include STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers, alongside early-stage programs addressing high unmet medical needs in cancer and autoimmune disorders. Operating in the biotechnology industry within the healthcare sector, the company is headquartered at 111 Oyster Point Boulevard in South San Francisco, California, with 178 employees led by CEO Ms. Jane Chung R.Ph. Sutro Biopharma, Inc. plays a significant role in the financial markets as a specialized biotech issuer, where its valuation reflects clinical trial advancements, regulatory approvals, and strategic partnerships characteristic of innovative drug development enterprises.